-+ 0.00%
-+ 0.00%
-+ 0.00%
MapLight Therapeutics Enters $100 Million At-the-Market Share Sale Agreement With Leerink Partners
Share
Listen to the news
MapLight Therapeutics Enters $100 Million At-the-Market Share Sale Agreement With Leerink Partners
  • MapLight Therapeutics entered a sales agreement with Leerink Partners on November 16, 2026, for a $100 million at-the-market voting common stock offering.
  • Leerink will receive a commission of up to 3% of gross sales under the agreement.
  • The company has no obligation to sell shares and may suspend sales or terminate the agreement at any time.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-462385), on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending